The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...
MINNEAPOLIS, July 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback